Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: RCT

19. Januar 2021 aktualisiert von: Yong In, The Catholic University of Korea

Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) has recently been reported to be effective in controlling pain in persistent chronic pain caused by joint surgery and arthritis. However, opioids are important drugs that still play a pivotal role in pain control after surgery. In this study, we want to investigate the difference of the result among patients who undego total knee arthroplasty (TKA), of the result of pain control after TKA from SNRI administration of duloxetine and opioid in two groups. We designed a randomized controlled study (RCT) for the effect of post-TKA pain control to determine whether SNRI is effective in controlling post-TKA pain compared to Opioid, and whether there is a difference in side effects.

Studienübersicht

Status

Unbekannt

Intervention / Behandlung

Detaillierte Beschreibung

For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be performed using the same pain control technique (pain control using NSAID) until discharge (1 week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is known as the patient's pain criterion, the study will be conducted only on patients whose score is more severe than 4 points. Among these subjects, only patients who agreed to the study will be assigned to the group taking duloxetine and the group taking opioids with the same probability according to the randomization table for one week after surgery, that is, upon discharge. In our hospital, almost all patients with total knee arthroplasty are discharged one week after surgery, except for special cases such as morbidity of systemic diseases such as cardiopulmonary dysfunction or acute infection after surgery.

Among the co-researchers, one researcher who is in charge of only patient assignment is selected, and the person in charge creates a randomization table through computer generated randomization. During the assignment process, the assignee will not know in advance the next assignment group, and the randomization table is kept in secret. The assignee does not intervene in any other process of this study, and participates only in the task of selecting the assigned group using random checks. The evaluation is evaluated by an evaluator who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study. Such a study plan will be fully explained to the patient in the process of seeking consent for the study before discharge, as it is recorded in detail in the subject description, and only patients who have obtained this consent will be the subject of the study.

This criterion is established because both duloxetine and opioid are not used for all patients after surgery, but for additional pain control after surgery. Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. In general, if duloxetine is not taken for more than 10 weeks, the frequency of discontinuation syndrome that can occur after discontinuation is remarkably low, so the administration period of 6 weeks was set as the administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups.

As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.

Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory (BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure additional pain scales in various ways. In addition, SF-36 will be measured before surgery, at 6 weeks, 3 months, 6 months, and 1 year after surgery.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

160

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults over age 19
  • Patients undergoing total knee arthroplasty for osteoarthritis of the knee joint
  • Patients with a pain VAS scale of 4 or more out of 10 after TKA with a pain in the knee joint during daily activities on flat ground
  • Patients who are willing or able to follow doctor's instructions, including joint exercises
  • Patients not participating in other clinical trials
  • Patients who have received sufficient explanation for this clinical trial and agreed to participate

Exclusion Criteria:

  • Patients with secondary knee osteoarthritis
  • Patients with hypersensitivity reactions and serious side effects to duloxetine or opioid
  • Patients with inflammatory arthritis or crystalline arthritis
  • Local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities.
  • Patients who underwent meniscus surgery on the knee joint in the painful area
  • If there is construction or deformation of the knee joint in the pain area
  • Patients with serious heart-related diseases such as cardiac arrest, a history of cerebral infarction, or ischemic heart disease
  • Patients with high blood pressure with poor blood pressure control (Systolic Blood Pressure of> 150 mmHg or Diastolic Blood Pressure> 95 mmHg)
  • Patients with abnormal liver function (ALT)> 2.0 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine> 2.0 times ULN)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental: Duloxetine group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Aktiver Komparator: Active comparator: Opioid group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain Visual Analogue Scale
Zeitfenster: changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
score ranges 0 to 10, higher score means more painful
changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
Brief pain inventory (BPI)
Zeitfenster: changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
includes 7 categories. each category score ranges 0 to 10, higher score means more painful
changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
WOMAC(Western Ontario and McMaster University Arthritis Index ) pain scale
Zeitfenster: changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). higher score means more painful.
changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
Intermittent and Constant Osteoarthritis pain (ICOAP) score
Zeitfenster: changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
11-item tool that assess pain at knee joint. The 11 items are scored froma 0 to 4 with 0 being no pain and 4 being extreme pain
changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
SF-36(Short Form Health Survey - 36) score
Zeitfenster: changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability
changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
Range of Motion
Zeitfenster: The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. Januar 2021

Primärer Abschluss (Voraussichtlich)

1. Dezember 2022

Studienabschluss (Voraussichtlich)

1. Dezember 2022

Studienanmeldedaten

Zuerst eingereicht

6. Januar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. Januar 2021

Zuerst gepostet (Tatsächlich)

22. Januar 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. Januar 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Januar 2021

Zuletzt verifiziert

1. Januar 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Arthrose, Knie

Klinische Studien zur Duloxetine vs. Opioid

Abonnieren